Despite this preliminary evidence, it remains unknown whether changes in CYP8B1 expression and CA:CDCA ratio impact enterohepatic FXR signaling and NAFLD progression. This evidence concerns the gene CYP8B1 and metabolic dysfunction-associated steatotic liver disease.